The DSMB clearance to escalate to the highest dose cohort is a strong safety signal that de-risks the program. The November 10 mg/kg data readout is the next major catalyst; a positive readout could significantly re-rate the stock. Monitor for any updates on the FDA partial clinical hold, which remains a risk.
Drug in focus
PEPG drug pipeline →PGN-EDODM1
▲ Bullish Named in this 8-K- Impact
- Phase
- Phase 2
- Time to market
- At least 2-3 years away, assuming positive Phase 2 data in November 2026, an end-of-Phase 2 meeting with regulators in 1H 2027, a subsequent Phase 3 program, and eventual NDA filing.
- Next catalyst
- None dated
What to watchWatch for the 10 mg/kg data readout from the FREEDOM2-DM1 study expected in November 2026, positive splicing-correction data could drive a significant re-rate given the stock's ~$3.11 price vs. the $10.19 mean analyst target. However, the unresolved FDA partial clinical hold and the active $100M ATM facility are overhangs that could cap upside or accelerate dilution.
How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Aug 6 $2.41entry
- T+1 · 3mo ago +18.26%α +17.65% · $2.85
- T+5 · 3mo ago +23.65%α +22.44% · $2.98
- T+20 · 3mo ago +31.95%α +31.35% · $3.18
- T+60 · 18d ago −2.07%α −0.40% · $2.36
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
PepGen reported Q2 2026 EPS of -$0.26, beating the -$0.30 consensus by 13.3%, with no revenue. The key catalyst is the DSMB's recommendation to advance PGN-EDODM1 into the highest 12.5 mg/kg dose cohort in the FREEDOM2-DM1 study and to dose-escalate the OLE, confirming a favorable safety profile. The company has $117.2M cash, sufficient into Q4 2027, and expects 10 mg/kg data in November 2026, which is the primary near-term catalyst.
Key Financial Metrics
Key Facts
- DSMB recommended advancing FREEDOM2 into the highest 12.5 mg/kg dose cohort with no protocol changes.
- DSMB also approved OLE dose escalation from 5 mg/kg to 10 mg/kg.
- 10 mg/kg FREEDOM2 cohort fully enrolled; 7 of 8 participants completed dosing; data expected November 2026.
- 12.5 mg/kg cohort results expected 1H 2027; EOP2 meeting with regulators planned thereafter.
- Cash, cash equivalents and marketable securities were $117.2M as of June 30, 2026, sufficient into Q4 2027.
- Net loss was $17.8M ($0.26 per share) vs $23.1M ($0.70 per share) in Q2 2025.
- EPS of -$0.26 beat consensus of -$0.30 by 13.3%.
- EMA granted Orphan Designation for PGN-EDODM1.
- No serious adverse events or dose-limiting toxicities reported in FREEDOM2 or OLE to date.
- 16 patients enrolled in FREEDOM-OLE at 5 mg/kg; 6 of 8 from 5 mg/kg FREEDOM2 cohort enrolled.
Financial Impact
EPS beat of 13.3% vs consensus; cash burn of ~$15.1M per quarter; cash runway extended into Q4 2027
Risk Factors
- FDA partial clinical hold on FREEDOM2 study remains unresolved.
- 10 mg/kg data in November may not replicate the splicing correction trends seen at lower doses.
- Dilution risk from potential future equity offerings to fund operations beyond current cash runway.
- Clinical-stage biotech with no approved products or revenue; binary event risk around data readouts.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 8 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-336767 |
| Document: pepg-20260806.htm | 0001193125-26-336767 |
| Document: pepg-ex99_2.htm | 0001193125-26-336767 |
| Document: pepg-ex99_3.htm | 0001193125-26-336767 |
| Document: 0001193125-26-336767-index-headers.html | 0001193125-26-336767 |
| Document: 0001193125-26-336767-index.html | 0001193125-26-336767 |
| Document: 0001193125-26-336767.txt | 0001193125-26-336767 |
| 8-K Data (Synthetic) | 0001193125-26-336767 |
Track record
12 reports on PEPG
4 of 6 bullish or bearish reports moved the stock their way by T+1. Best: +14.10% at T+1 after the Nov 10, 2026 report. 5 of 6 went positive at some point.
Filters
- Nov 12, 20264d ago 8-K Bearish 6/10 Entry $4.36 to $4.19 Now $4.19 +3.90% ▲ +3.90% +1.99% vs SPY
- Nov 12, 20264d ago 424B5 Bearish 6/10 Entry $4.36 to $4.19 Now $4.19 +3.90% ▲ +3.90% +1.99% vs SPY
- Nov 10, 20266d ago 424B5 Bearish 6/10 Entry $5.26 to $5.04 Now $4.19 +20.34% ▲ +4.18% +3.83% vs SPY
- Nov 10, 20266d ago 8-K Bullish 7/10 Entry $4.61 to $5.26 Now $4.19 −9.11% ▲ +14.10% +12.78% vs SPY
- Aug 6, 202614w ago 8-K Bullish 7/10 Viewing Entry $2.41 to $2.85 Now $4.19 +73.86% ▲ +18.26% +17.65% vs SPY
- Jun 11, 202622w ago Institutional Cluster Neutral 2/10 Entry $1.51 to $1.47 Now $4.19 +177.48% ▼ −2.65% −3.19% vs SPY
- Jun 11, 202622w ago Institutional Cluster Neutral 3/10 Entry $1.51 to $1.47 Now $4.19 +177.48% ▼ −2.65% −3.19% vs SPY
- May 22, 202625w ago EFFECT Bearish 7/10 Entry $1.51 to $1.53 Now $4.19 −177.48% ▼ −1.32% −0.74% vs SPY
- May 19, 202625w ago S-3 Bearish 7/10 Entry $1.38 to $1.44 Now $4.19 −203.62% ▼ −4.35% −3.31% vs SPY
- May 12, 202626w ago 8-K Neutral 5/10 Entry $1.78 to $1.78 Now $4.19 +135.39% · 0.00% +0.00% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers